Literature DB >> 8474077

Assessment of nonarticular tenderness and prevalence of fibromyalgia in children.

D Buskila1, J Press, A Gedalia, M Klein, L Neumann, R Boehm, S Sukenik.   

Abstract

Fibromyalgia syndrome (FS) is most common in midlife, but may be seen at any age. Its prevalence and assessment of tenderness in healthy children is not known. We assessed 338 healthy schoolchildren for tenderness thresholds and prevalence of FS. In all children a point count of 18 tender points (TP) was conducted by thumb palpation and tenderness of some of the TP sites as well as control point sites was further assessed using a Chatillon dolorimeter. All children and their parents were questioned about the presence of widespread pain or aching. Children were considered to have FS if they met the American College of Rheumatology (ACR) criteria for diagnosis of FS. Of the 338 children, 21 (6.2%) had FS. Thresholds of tenderness of 9 TP were 5.0 (1.2) (kg) [mean (standard deviation)] for boys vs 3.6 (0.8) (kg) for girls (p < 0.001). Thresholds of tenderness of the control point sites were 7.1 (1.4) (kg) for boys vs 5.5 (1.1) (kg) for girls (p < 0.001). Thresholds of tenderness of TP and control points in the children with FS were 2.5 (0.4) (kg) and 4.2 (0.5) (kg) vs 4.5 (1.2) (kg) and 6.6 (1.4) (kg) respectively in the children without FS (p < 0.001). We suggest that FS is common in the pediatric age group. Boys have lower tenderness than girls; children with FS have lower thresholds for tenderness both at control and TP compared to the subjects without FS.

Entities:  

Mesh:

Year:  1993        PMID: 8474077

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  29 in total

1.  Chronic musculoskeletal and other idiopathic pain syndromes.

Authors:  P N Malleson; H Connell; S M Bennett; C Eccleston
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

2.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

Review 3.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

Review 4.  Epidemiology of fibromyalgia.

Authors:  Lily Neumann; Dan Buskila
Journal:  Curr Pain Headache Rep       Date:  2003-10

5.  Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood.

Authors:  Susmita Kashikar-Zuck; Natoshia Cunningham; Soumitri Sil; Maggie H Bromberg; Anne M Lynch-Jordan; Daniel Strotman; James Peugh; Jennie Noll; Tracy V Ting; Scott W Powers; Daniel J Lovell; Lesley M Arnold
Journal:  Pediatrics       Date:  2014-02-24       Impact factor: 7.124

6.  Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography.

Authors:  Pamela F Weiss; Nancy A Chauvin; Andrew J Klink; Russell Localio; Chris Feudtner; Diego Jaramillo; Robert A Colbert; David D Sherry; Ron Keren
Journal:  Arthritis Rheumatol       Date:  2014-01       Impact factor: 10.995

Review 7.  Fibromyalgia: Treating Pain in the Juvenile Patient.

Authors:  Sabrina Gmuca; David D Sherry
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

8.  Recent developments in the understanding of paediatric musculoskeletal pain syndromes.

Authors:  T R Southwood
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

Review 9.  Juvenile Fibromyalgia: Different from the Adult Chronic Pain Syndrome?

Authors:  Susmita Kashikar-Zuck; Christopher King; Tracy V Ting; Lesley M Arnold
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

10.  Joint hypermobility and fibromyalgia in schoolchildren.

Authors:  A Gedalia; J Press; M Klein; D Buskila
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.